IRIDEX Corp

IRIDEX Corp's capital structure shows a liquidity position of $6.03 million in cash and equivalents, with a current ratio of 1.91, indicating moderate short-term liquidity. The company's price-to-book ratio of 3.57 suggests the market is valuing the firm at a premium to its book value, despite a negative return on equity of -90.15% and a negative return on assets of -15.22%. The debt-to-equity ratio of 0.76 reflects a relatively conservative leverage position, with long-term debt of $3.74 million against total equity of $4.92 million. Profitability metrics show a challenging operating environment, with a net loss of $4.44 million and an operating loss of $2.57 million in the latest period. Gross profit of $19.23 million represents 36.5% of revenue, which is below the industry median for Advanced Medical Equipment & Technology firms, where gross margins typically exceed 45%. The company's EBITDA multiple is negative at -5.94, indicating a lack of earnings to support debt or equity valuation. Geographically, IRIDEX Corp's revenue is concentrated in the United States, with no material international operations disclosed in the latest financials. The company operates in a single business segment focused on laser-based medical devices, with no diversification across product lines or therapeutic areas. Growth trajectory is mixed, with revenue of $52.68 million in the latest period. Analysts have assigned a mean price target of $2.75, implying a 172% upside from the current market price of $1.01. However, the company's free cash flow of -$4.06 million and operating cash flow of -$2.12 million suggest ongoing cash burn, which could limit growth capacity without external financing. Risk factors include a low liquidity score and a negative operating cash flow, which could constrain the company's ability to fund operations without additional capital. Dilution risk is currently low, with no immediate filing-based flags detected, and shares outstanding remain unchanged at 17.4 million for both basic and diluted shares. No recent filings or transcripts indicate material operational or strategic changes in the past 90 days. Recent analyst sentiment is neutral, with one "buy" recommendation and no "strong buy" or "hold" ratings. The mean recommendation score of 2.00 suggests a cautious outlook, with no consensus for aggressive investment.